IND 22 - Latest Innovations and a Glimpse into the Future of Contrast-Enhanced MRI

Gadolinium-based contrast agents (GBCAs) have been used in over 800 million contrast-enhanced MRI (CE-MRI) applications worldwide in both patient diagnosis and follow-up scans. The unique in-vivo properties of GBCAs have enabled their widespread adoption, providing valuable diagnostic information across a broad range of indications and serving as an effective option for enhancing the MRI signal intensity.


We provide an important update for all those involved in CE-MRI. This session will focus on the latest innovations and ongoing developments in next-generation macrocyclic GBCAs. An expert multi-specialty panel will discuss the need for optimized utilization of contrast agents in the context of international guidelines, environmental sustainability and patient preferences, setting the scene for the future of CE-MRI.


Essential information of Gadovist is located at Bayer booth.


Gadoquatrane has not been approved in the European Union yet.


PP-GD-ALL-0002-1 11.2024